Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505990-34-00

Enrollment

183

Registered

2024-03-08

Start date

2024-11-08

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Brief summary

Event-free survival (EFS) at 3 years, EFS, Progression-free survival (PFS), Overall survival (OS), Lymphoma-specific survival (LSS), Overall response rate (ORR), Complete response rate (CRR), Response rates after 6 cycles, Response rates at final assessment in trial, Response duration

Detailed description

Treatment-related mortality/Non-lymphoma mortality, Time from diagnostic biopsy to start of chemotherapy and to start of steroids., Number and duration of scheduled and unscheduled hospital admissions, Use of IV antibiotics, Total number of hospital days, Time between chemotherapy regimens and total time from starting to ending treatment within trial, Reconstitution of T-cell (cellular and humoral) immunity, Time on sick leave, Long-term cardiac toxicity, Second primary malignancies

Interventions

DRUGDOXORUBICIN HYDROCHLORIDE

DRUGMethotrexate Ebewe

DRUG100 mg/ml

DRUGkoncentrat till infusionsvätska

DRUGlösning

DRUGVINCRISTINE SULFATE

DRUGVepesid 50 mg mjuka kapslar

DRUGPrednisolon Pfizer 10 mg tabletter

DRUGCYCLOPHOSPHAMIDE

DRUGEtoposid Fresenius Kabi 20 mg/ml - koncentrat till infusionsvätska

DRUGMabThera 500 mg concentrate for solution for infusion

DRUGNordimet 15 mg solution for injection in pre-filled pen

DRUGDexametasona Krka 4 mg comprimidos

DRUGCytarabine STADA 100 mg/ml koncentrat till infusionsvätska

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Event-free survival (EFS) at 3 years, EFS, Progression-free survival (PFS), Overall survival (OS), Lymphoma-specific survival (LSS), Overall response rate (ORR), Complete response rate (CRR), Response rates after 6 cycles, Response rates at final assessment in trial, Response duration	—

Secondary

Measure	Time frame
Treatment-related mortality/Non-lymphoma mortality, Time from diagnostic biopsy to start of chemotherapy and to start of steroids., Number and duration of scheduled and unscheduled hospital admissions, Use of IV antibiotics, Total number of hospital days, Time between chemotherapy regimens and total time from starting to ending treatment within trial, Reconstitution of T-cell (cellular and humoral) immunity, Time on sick leave, Long-term cardiac toxicity, Second primary malignancies	—

Measure

Time frame

—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026